World AI Cannes Festival: must-see speakers in 2023
24.1.2023 11:25:00 EET | Business Wire | Press release
The World AI Cannes Festival will take place in Cannes on February 9, 10 and 11 2023. This is the top world event dedicated exclusively to AI, tech leaders innovating in AI and the economic, human and societal issues that will impact our lives in the short term.
The event is a chance to get up to speed on the current marketplace, learn from the best experts and to meet decision-makers and top business leaders. Many notable speakers will deliver presentations and lead strategic conferences, think-tank workshops, exhibition stands and networking sessions.
Spotlight on the major speakers for 2023
The WAICF is an opportunity for artificial intelligence professionals and experts , whether from professional backgrounds, research or public administrations, to meet and exchange views on developments in the sector.
The 100+ international speakers at the WAICF in 2023 will include:
- Yann Lecun, Vice-President and Chief AI Scientist, Meta AI
- Joann Stonier, Chief Data Officer, Mastercard
- Wolfgang Hauner, Head of Group Data Analytics, Allianz
- Saeed Contractor, Global Head of Intelligent Automation COE, Uber
- Manuela M. Veloso, Head, J. P. Morgan Chase AI Research
- Xavier Lagardere, Chief Data Officer, Vice President Data Strategy and Transformation, Lufthansa Group
- Stuart Russell, Professor of Computer Science and Michael H. Smith and Lotfi A. Zadeh Chair in Engineering, University of California, Berkeley
- Alberto Prado, Vice-President, Global Head of R&D Digital & Partnerships, Unilever
- Divya Dwivedi, Advocate, Supreme Court of India
- Aidan Gomez, Co-Founder and CEO, Cohere
- Thomas Wolf, Co-Founder and Chief Science Officer, Hugging Face
- John Kamara, Founder and CEO/founder, Adanian Labs/AI Center of Excellence (AICE)
- Michael Kearns, Amazon Scholar, University of Pennsylvania
- Michaela Schutt, SVP, Head of Global Talent Acquisition Ecosystem, Siemens
- Nozha Boujemaa, Global VP - Digital Ethics and Responsible AI, IKEA Retail
- Oren Etzioni, CEO, Allen Institute for AI
The Festival will provide an overview of AI in all its diversity through 5 key conference tracks:
- AI FOR SOCIETY: Understand the benefits of AI for society and our planet, and the challenges that must be met.
- AI TODAY AND TOMORROW: Explore what AI can do today, and picture what future innovations will offer tomorrow's society and organizations.
- AI STRATEGY: Get key insights to improve your AI strategy and take your business to the next level.
- AI TECHNOLOGY: Learn how best to use the different AI technologies, and shape your innovation mindset with top-level speakers.
- AI APPLICATIONS: Get an overview of the advances organizations can make using AI, through focuses on various industries.
Full list of conferences and speakers
Get accreditation through the media pass site
About World AI Cannes Festival
The World AI Cannes Festival brings together industry experts, professionals, and the general public to attend exhibitions, workshops, happenings, conferences, networking and meet-ups with an international dimension. The rich and varied program highlights the latest AI applications in business and in everyday life. A unique opportunity for national and international institutions, associations, businesses and start-ups across the world to meet their target audiences, highlight their expertise and demonstrate their commitment to ethical and sustainable AI.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005541/en/
Contact information
Press contacts WAICF 2023
Profile Agency –
waicf@agence-profile.com
Jennifer Loison – 06 10 22 52 37 | Shérazade El Houari – 06 22 35 69 79
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom